For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-35756 Washington, D.C. 20549 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 Florida 33912 Nevada 74-2897368 (Address of principal executive ...

Exhibit 99.1 GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights GAITHERSBURG, Md., July 29, 2025 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. "Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-8923 WELLTOWER INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of Incorporation) Delaware ...

___________________________________________________________________________________________ (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________________________________ FORM 10-Q Commission File Number: 001-35669 _____________________________________________________________________ SHUTTERSTOCK, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

EXHIBIT 99.1 Revenue Second quarter revenue of $267.0 million increased by $46.9 million or 21% as compared to the second quarter of 2024. Revenue from our Content product offering increased by $29.8 million, or 18%, as compared to the second quarter of 2024, to $199.8 million. Envato, which was acquired in July of 2024, contributed to the year-over-year increase. Content revenue represented 75% of our total revenue in the second quarter of 2025. Revenue generated from our Data, Distribution, and Services p ...

Exhibit 99.1 uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to__________ Commission File Number: 000-49728 JETBLUE AIRWAYS CORPORATION (Exact name of registrant as specified in its charter) (State or o ...

Exhibit 99.1 NeoGenomics Reports Second Quarter 2025 Results Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance Fort Myers, Florida (July 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 202 ...

收入和利润（同比环比） - 公司第二季度收入增长16%至98亿美元[2][3] - 2025年第二季度公司总收入为97.54亿美元，同比增长16.2%[31] - 2025年第二季度调整后净收入为56.68亿美元，同比增长14%[31] - 2025年第二季度营业利润为3.74亿美元，同比增长52%[31] - 2025年第二季度归属于公司的净利润为2.15亿美元，同比增长65.4%[31] - 2025年第二季度每股基本收益为0.72美元，同比增长71.4%[31] - 2025年第二季度总营收为97.54亿美元，同比增长16.2%（2024年同期为83.91亿美元）[33][35] - 核心业务调整后净收入为56.68亿美元，同比增长14.1%（2024年同期为49.71亿美元）[33][35] - 2025年上半年净利润4.31亿美元，较2024年同期的2.9亿美元增长48.6%[39] - 2025年上半年核心调整后净利润6.18亿美元，较2024年同期的4.89亿美元增长26.4%[47] - 2025年上半年核心稀释每股收益2.05美元，较2024年同期的1.59美元增长28.9%[47] - 2025年第二季度净收入为2.39亿美元，同比增长68.3%（2024年同期为1.42亿美元）[48] 成本和费用（同比环比） - 2025年第二季度成本与费用合计93.99亿美元，同比增长15.4%[31] - 2025年第二季度折旧与摊销费用为1.82亿美元，同比增长13%[31] - 2025年第二季度利息支出净额为5900万美元，同比下降6.3%[31] - 2025年第二季度有效税率为20.3%，同比上升8.3个百分点[31] - 总成本与费用为93.99亿美元，同比增长15.3%（2024年同期为81.45亿美元）[33][35] - 折旧与摊销费用为1.82亿美元，同比增长13%（2024年同期为1.61亿美元）[33][35] - 2025年第二季度折旧与摊销费用为1.82亿美元，同比增长13%（2024年同期为1.61亿美元）[48] - 2025年第二季度收购相关整合成本为7500万美元，同比增加476.9%（2024年同期为1300万美元）[48] - 2025年第二季度利息净支出为5900万美元，同比下降6.3%（2024年同期为6300万美元）[48] 核心EBITDA表现 - 核心EBITDA增长30%至6.58亿美元[2][3] - 2025年上半年核心EBITDA达11.98亿美元，同比增长28.8%[31] - 核心EBITDA为6.58亿美元，同比增长30.3%（2024年同期为5.05亿美元）[33][35] - 2025年第二季度核心EBITDA为6.58亿美元，同比增长30.3%（2024年同期为5.05亿美元）[48] - 2025年上半年核心EBITDA为11.98亿美元，同比增长28.8%（2024年同期为9.3亿美元）[48] - 截至2025年6月30日的过去12个月核心EBITDA为29.72亿美元[48] 各业务线表现 - 全球租赁收入增长14%达到公司历史第二季度最高水平[5] - 全球物业销售收入增长20%超出预期[8] - 抵押贷款发起收入增长44%[8] - 设施管理收入增长17%[9] - 项目管理收入增长14%[14] - 资产管理规模(AUM)增长62亿美元至1553亿美元[15] - 房地产投资部门运营利润为2500万美元，同比增长150%（2024年同期为1000万美元）[33][35] - 顾问服务部门运营利润为3.8亿美元，同比增长32.4%（2024年同期为2.87亿美元）[33][35] - 建筑运营与体验部门营收为57.64亿美元，同比增长18.7%（2024年同期为48.55亿美元）[33][35] - 项目管理部门营收为17.86亿美元，同比增长14.3%（2024年同期为15.63亿美元）[33][35] - 企业部门运营亏损为1.29亿美元，同比扩大24.1%（2024年同期为1.07亿美元）[33][35] - 2025年第二季度房地产投资部门营业利润为2500万美元，同比增长150%（2024年同期为1000万美元）[49] - 2025年第二季度全球房地产开发业务扭亏为盈，营业利润300万美元（2024年同期亏损2600万美元）[49] 现金流和流动性 - 公司流动性增加12亿美元至47亿美元[2][18] - 公司自由现金流在第二季度为200万美元[20] - 2025年上半年经营活动净现金流出4.89亿美元，较2024年同期的2.05亿美元流出扩大138.5%[39] - 2025年上半年资本支出1.38亿美元，与2024年同期1.35亿美元基本持平[39] - 过去12个月自由现金流为12.62亿美元，其中资本支出3.1亿美元[49] - 2025年上半年商业票据净融资11.82亿美元，2024年同期无此项融资[39] - 2025年上半年长期债务融资16.74亿美元，较2024年同期的4.95亿美元增长238.2%[39] 资产和负债 - 公司2025年6月30日总资产为276.93亿美元，较2024年12月31日的243.83亿美元增长13.6%[37] - 现金及现金等价物从2024年底的11.14亿美元增至2025年6月的13.95亿美元，增幅25.2%[37] - 应收账款净额从2024年底的70.05亿美元增至2025年6月的73.19亿美元，增长4.5%[37]

Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. – July 29, 2025 – Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company's clinical development portfolio. "As I begin my tenure as CEO, I look forward to leading Incyte through its next phase of growth and value creation for patients, pa ...